...
首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >Two novel D151Y and M391T LDLR mutations causing LDLR transport defects in Thai patients with familial hypercholesterolemia.
【24h】

Two novel D151Y and M391T LDLR mutations causing LDLR transport defects in Thai patients with familial hypercholesterolemia.

机译:在泰国家族性高胆固醇血症患者中,两个新的D151Y和M391T LDLR突变导致LDLR转运缺陷。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused by mutations in the low density lipoprotein receptor (LDLR) gene. Two novel LDLR mutations, D151Y and M391T, had been previously identified in unrelated Thai patients with heterozygous FH. To confirm that these mutations cause FH, the functional characteristics of D151Y and M391T, which are located in the fourth cysteine repeat of the ligand-binding domain and in the sixth YWTD repeat of the epidermal growth factor precursor homology domain, respectively, were studied. METHODS: CHO-ldlA7 cells were transfected with wild type and mutant LDLR cDNAs. Thereafter, the localization, expression, and ability of LDL uptake of LDLR were evaluated by confocal laser scanning microscope (CLSM), and flow cytometry. RESULTS: CLSM revealed both D151Y and M391T LDLR were partially retained in the endoplasmic reticulum, with the remaining residual activity observed by LDL uptake. Similarly, flow cytometric analysis showed a significant reduction of LDLR expression to 18% and 38% and of LDL uptake to 15% and 71% in D151Y and M391T LDLR, respectively. CONCLUSIONS: The transport defect of LDLR contributes to the pathology of FH. These data are useful for an insight inspires the development of novel lipid-lowering drugs with beneficial therapeutic value.
机译:背景:家族性高胆固醇血症(FH)是由低密度脂蛋白受体(LDLR)基因突变引起的常染色体显性遗传疾病。先前已经在泰国的杂合性FH患者中发现了两个新的LDLR突变D151Y和M391T。为了证实这些突变引起FH,研究了D151Y和M391T的功能特性,分别位于配体结合结构域的第四个半胱氨酸重复序列和表皮生长因子前体同源结构域的第六个YWTD重复序列中。方法:野生型和突变的LDLR cDNAs转染CHO-ldlA7细胞。此后,通过共聚焦激光扫描显微镜(CLSM)和流式细胞仪评估了LDLR的LDL摄取的定位,表达和能力。结果:CLSM揭示D151Y和M391T LDLR均部分保留在内质网中,而通过LDL摄取可观察到剩余的残留活性。同样,流式细胞仪分析显示D151Y和M391T LDLR的LDLR表达分别显着降低至18%和38%,LDL摄取分别降低至15%和71%。结论:LDLR的运输缺陷是造成FH的病理原因。这些数据有助于洞察激发具有有益治疗价值的新型降脂药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号